OpenEvidence Partners with Anticoagulation Forum to Integrate AI-Driven Antithrombotic Guidance — OpenEvidence

Event summary

OpenEvidence and the Anticoagulation Forum (AC Forum) announced a strategic partnership on July 8, 2026 to provide AI-enabled antithrombotic guidance for clinicians.
The collaboration combines AC Forum’s clinical expertise with OpenEvidence’s AI platform to support decision-making in complex antithrombotic therapy cases.
Antithrombotic medications are a leading cause of preventable medication-related harm, and the partnership aims to improve consistency in best practices.
AC Forum’s resources will be integrated into OpenEvidence’s platform, with real-world use data informing future clinical guidance development.

The big picture

This partnership aligns with the broader trend of AI integration in clinical decision support, particularly in high-stakes areas like antithrombotic therapy. The collaboration addresses a critical gap in consistent best practices, leveraging OpenEvidence’s widespread adoption among U.S. clinicians and AC Forum’s global expertise to potentially set new standards in antithrombotic stewardship.

What we're watching

Adoption Pace: How quickly clinicians will integrate AI-driven antithrombotic guidance into their workflows.
Impact on Outcomes: Whether the partnership can reduce preventable medication-related harm in antithrombotic therapy.
Scalability: The pace at which OpenEvidence and AC Forum can expand this model to other high-risk medical areas.